{
    "organizations": [],
    "uuid": "069f3c9cd27d1ce89006732c2104b09c38453c4a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-portola-pharmaceuticals-announces/brief-portola-pharmaceuticals-announces-new-interim-results-from-ongoing-annexa-4-study-idUSFWN1QU0Z0",
    "ord_in_thread": 0,
    "title": "BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12, 2018 / 4:20 PM / Updated 7 minutes ago BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study Reuters Staff 1 Min Read March 12 (Reuters) - Portola Pharmaceuticals Inc: * PORTOLA PHARMACEUTICALS ANNOUNCES NEW INTERIM RESULTS FROM ONGOING ANNEXA-4 STUDY OF FACTOR XA INHIBITOR REVERSAL AGENT ANDEXXAÂ® (ANDEXANET ALFA) IN PATIENTS WITH LIFE-THREATENING BLEEDING * PORTOLA PHARMACEUTICALS INC - THE INTERIM RESULTS INCLUDED SAFETY DATA FROM 227 OF 228 ENROLLED PATIENTS * PORTOLA PHARMACEUTICALS INC - EXCELLENT OR GOOD HEMOSTASIS ACHIEVED IN 83 PERCENT OF PATIENTS IN ANNEXA-4 * PORTOLA PHARMACEUTICALS INC - ANDEXANET ALFA IS CURRENTLY UNDER REVIEW BY U.S. FDA WITH AN ASSIGNED ACTION DATE OF MAY 4, 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-03-12T18:17:00.000+02:00",
    "crawled": "2018-03-12T18:36:56.047+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "announces",
        "new",
        "interim",
        "result",
        "ongoing",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "portola",
        "pharmaceutical",
        "inc",
        "portola",
        "pharmaceutical",
        "announces",
        "new",
        "interim",
        "result",
        "ongoing",
        "study",
        "factor",
        "xa",
        "inhibitor",
        "reversal",
        "agent",
        "andexanet",
        "alfa",
        "patient",
        "bleeding",
        "portola",
        "pharmaceutical",
        "inc",
        "interim",
        "result",
        "included",
        "safety",
        "data",
        "enrolled",
        "patient",
        "portola",
        "pharmaceutical",
        "inc",
        "excellent",
        "good",
        "hemostasis",
        "achieved",
        "percent",
        "patient",
        "portola",
        "pharmaceutical",
        "inc",
        "andexanet",
        "alfa",
        "currently",
        "review",
        "fda",
        "assigned",
        "action",
        "date",
        "may",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}